Genetic profiling as a marker for risk of sudden cardiac death

Current Opinion in Cardiology

Volumn 21, Issue 1, 2006, Pages 42-46

  Gollob, Michael H ^a  

^a UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

Author keywords

Arrhythmias; Genetics; Heart failure; Implantable cardioverter defibrillator; Sudden cardiac death

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALDOSTERONE SYNTHASE; AMIODARONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSINOGEN; BETA 1 ADRENERGIC RECEPTOR; BISOPROLOL; CALCIUM; CONNEXIN 43; CONNEXIN 45; DESIPRAMINE; LOSARTAN; METOPROLOL; PHOSPHOLAMBAN; POTASSIUM CHANNEL; RYANODINE RECEPTOR; SODIUM CALCIUM EXCHANGE PROTEIN; VOLTAGE GATED SODIUM CHANNEL;

ARRHYTHMOGENESIS; BIOENERGY; BRUGADA SYNDROME; CALCIUM HOMEOSTASIS; CARDIOVASCULAR RISK; CLINICAL GENETICS; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE MARKER; DISEASE SEVERITY; FOLLOW UP; GENETIC ANALYSIS; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOMICS; HEALTH CARE COST; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART VENTRICLE ARRHYTHMIA; HIGH RISK POPULATION; HUMAN; IMPLANTATION; INTERMETHOD COMPARISON; LONG QT SYNDROME; MORTALITY; NONHUMAN; PREDICTION; PRIMARY PREVENTION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SUDDEN DEATH; SYMPTOM; THERAPY EFFECT; TREATMENT INDICATION; VALIDATION STUDY;

EID: 32044456191     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hco.0000198982.86131.64     Document Type: Review

References (37)

1. Moss AJ, Hall J, Cannom DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med 1996; 26:1933-1939.
2. Buxton AE, Lee KL, Fisher JD, et al. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999; 341:1882-1890.
3. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346:877-883.
4. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352:225-237. This paper provides evidence that an empiric approach of ICD implantation in all heart failure patients with mild to moderate symptoms and ejection fraction ≤ 35% reduces mortality.
5. Wolpert C, Kuschyk J, Aramin N, et al. Incidence and electrophysiological characteristics of spontaneous ventricular tachyarrhythmias in high risk coronary patients and prophylactic implantation of a defibrillator. Heart 2004; 90:667-671. Data in this study indicate that 56.1 % of patients meeting MADIT I criteria for ICD implantation did not receive appropriate ICD therapy over an average follow-up of 2.5 years.
6. Yang P, Kanki H, Drolet B, et al. Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation 2002; 105:1943-1948.
7. Splawski I, Timothy KW, Tateyama M, et al. Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science 2002; 297:1333-1336.
8. Chow BJ, Gollob M, Birnie D. Brugada syndrome precipitated by a tricyclic anti-depressant. Heart 2005; 91:651.
9. Makielski JC, Ye B, Valdivia CR, et al. A ubiquitous splice variant and a common polymorphism affect heterologous expression of recombinant human SCN5A heart sodium channels. Circ Res 2003; 93:821-828.
10. Anson BD, Ackerman MJ, Tester DJ, et al. Molecular and functional characterization of common polymorphisms in HERG (KCNH2) potassium channels. Am J Physiol Heart Circ Physiol 2004; 286:H2434-H2441.
11. Tan BH, Valdivia CR, Rok BA, et al. Common human SCN5A polymorphisms have altered electrophysiology when expressed in Q1077 splice variants. Heart Rhythm 2005; 2:741-747. This study demonstrated that common genetic variations may exert functional differences in ion channel behaviour.
12. CIBIS-II investigators. The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet 1999; 353:9-13.
13. MERIT-HF study group. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353:2001-2007.
14. Levin MC, Marullo S, Muntaner O, et al. The myocardium-protective Gly-49 variant of the beta 1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. J Biol Chem 2002; 277:30429-30435.
15. Ranade K, Jorgenson E, Sheu WH, et al. A polymorphism in the beta1 adrenergic receptor is associated with resting heart rate. Am J Hum Genet 2002; 70:935-942.
16. Borjesson M, Magnusson Y, Hjalmarson A, Andersson B. A novel polymorphism in the gene coding for the beta(1)-adrenergic receptor associated with survival in patients with heart failure. Eur Heart J 2000; 21:1853-1858.
17. Iwai C, Akita H, Shiga N, et al. Suppressive effect of the Gly389 allele of the beta1-adrenergic receptor gene on the occurrence of ventricular tachycardia in dilated cardiomyopathy. Circ J 2002; 66:723-728.
18. Mason DA, Moore JD, Green SA, Liggett SB. A gain-of-function polymorphism in a G-protein coupling domain of the human beta1-adrenergic receptor. J Biol Chem 1999; 274:12670-12674.
19. Blumenfeld JD, Sealey JE, Mann SJ, Bragat A, et al. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects. Am J Hypertens 1999; 12:451-459.
20. Pitt B, Zannad F, Remme WJ, et al. The effects of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341:709-716.
21. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342:145-153.
22. Seidman JG, Seidman C. The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms. Cell 2001; 104:557-567.
23. Takeishi Y, Walsh RA. Cardiac hypertrophy and failure: lessons learned from genetically engineered mice. Acta Physiol Scand 2001; 173:103-111.
24. Lim DS, Lutucuta S, Bachireddy P, et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001; 103:789-791.
25. Bedi MS, Postava LA, Murali S, et al. Interaction of implantable defibrillator therapy with angiotensin-converting enzyme deletion/insertion polymorphism. J Cardiovasc Electrophysiol 2004; 15:1162-1166.
26. Pacifico A, Henry PD. Structural pathways and prevention of heart failure and sudden death. J Cardiovasc Electrophysiol 2003; 14:764-775.
27. Kanno S, Saffitz JE. The role of myocardial gap junctions in electrical conduction and arrhythmogenesis. Cardiovasc Pathol 2001; 10:169-177.
28. Spach MS, Josephson ME. Initiating reentry: the role of nonuniform anisotrophy in small circuits. J Cardiovasc Electrophysiol 1994; 5:182-209.
29. Lerner DL, Yamada KA, Schuessler RB, Saffitz JE. Accelerated onset and increased incidence of ventricular arrhythmias induced by ischemia in Cx43-deficient mice. Circ 2000; 101:547-552.
30. Gutstein DE, Morley GE, Tamaddon H, et al. Conduction slowing and sudden arrhythmic death in mice with cardiac-restricted inactivation of connexin43. Circ Res 2001; 88:333-339.
31. Yao JA, Gutstein DE, Liu F, et al. Cell coupling between ventricular myocyte pairs from connexin43-deficient murine hearts. Circ Res 2003; 93:736-743.
32. Pogwizd SM, Bers DM. Calcium cycling in heart failure: the arrhythmia connection. J Cardiovasc Electrophysiol 2002; 13:88-91.
33. Pogwizd SM, Bers DM. Cellular basis of triggered arrhythmias in heart failure. Trends Cardiovasc Med 2004; 14:61-66.
34. Omichi C, Lamp ST, Lin SF, et al. Intracellular Ca dynamics in ventricular fibrillation. Am J Physiol Heart Circ Physiol 2004; 286:H1836-H1844.
35. del Monte F, Johnson CM, Stepanek AC, et al. Defects in calcium control. J Card Fail 2002; 8:S421-S431.
36. Toyofuku T, Kurzydlowski K, Tada M, MacLennan DH. Amino acids Lys-Asp-Asp-Lys-Pro-Val402 in the Ca(2+)-ATPase of cardiac sarcoplasmic reticulum are critical for functional association with phospholamban. J Biol Chem 1994; 269:22929-22932.
37. Jiang D, Xiao B, Yang D, et al. RyR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload calcium release (SOICR). Proc Natl Acad Sci U S A 2004; 101:13602-13607.